Novartis Investor Relations Novartis New Organizational Model Powering our next phase of innovation, growth, and productivity Investor presentation April 04, 2022 Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding our ne ...

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix û Q4 2021 Results Investor presentation 1 Investor Relations │ Q4 2021 Results U NOVARTIS | Reimagining Medicine 2 NOVARTIS Q4 RESULTS | FEBRUARY 2, 2022 | NOVARTIS INVESTOR PRESENTATION Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform ...

Novartis AG (NYSE:NVS) Q4 2021 Earnings Conference Call February 2, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, IR Vasant Narasimhan - CEO Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology Harry Kirsch - CFO Richard Saynor - CEO, Sandoz John Tsai - Head, Global Drug Development & Chief Medical Officer Conference Call Participants Graham Parry - Bank of America Merrill Lynch Richard Parkes - BNP Paribas Laura Sutcliffe - UBS Andrew ...

As filed with the Securities and Exchange Commission on February 2, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSU ...

Novartis Fourth Quarter and Full Year 2021 Condensed Financial Report – Supplementary Data | INDEX | Page | | --- | --- | | GROUP AND DIVISIONAL OPERATING PERFORMANCE | | | Group | 3 | | Innovative Medicines | 7 | | Sandoz | 14 | | CASH FLOW AND GROUP BALANCE SHEET | 16 | | INNOVATION REVIEW | 19 | | CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | | | Consolidated income statements | 22 | | Consolidated statements of comprehensive income | 24 | | Consolidated balance sheets | 25 | | Consolidated statements of ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------|------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | Agenda | Novartis R&D Day | | | | | | | | | Speakers | | | | | | | | | | Novartis Strategy and Growth Story | | | | | | | | | | Cardiovascular and Renal | | | | | | | | | | Immunology, Hepatology & Dermatology | December 2, 2021 | | | | | | | | | Neuroscience | | | | | | | | | | Oncology | | | | | | | | | | | | | | | ...

Novartis AG (NYSE:NVS) Q3 2021 Earnings Conference Call October 26, 2021 8:00 AM ET Company Participants Vas Narasimhan – Chief Executive Officer Samir Shah – Global Head of Investor Relations Harry Kirsch – Chief Financial Officer Marie France – President of Novartis Pharmaceuticals Susanne Schaffert – President of Novartis Oncology John Tsai – Head of Global Drug Development and Chief Medical Officer Richard Saynor – Chief Executive Officer Karen Hale – Chief Legal Officer Conference Call Participants Gra ...

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References û Q3 2021 Results Investor presentation U NOVARTIS | Reimagining Medicine 1 Investor Relations │ Q3 2021 Results 2 Novartis Q3 Results | October 26, 2021 | Novartis Investor Presentation Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securi ...

As filed with the Securities and Exchange Commission on January 26, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSU ...

As filed with the Securities and Exchange Commission on January 29, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSU ...